When you're peddling a research report for the astounding price of $3800 you'd think you'd take the time to be sure your pitch has been proofread.
Not the Datamonitor people. Or perhaps the blame goes to the shoddy coders at Pharmaceutical Business Review Online.
Whichever. One of them is responsible for this:
Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population...
Despite the substantial impact IBS can have on sufferers' well being, about 7080% of sufferers have not been formerly diagnosed.
Wow! No wonder those of us with IBS feel so lousy. We each have it ten times over.
And this in a report whose justification of its price is so that you can:
Quantify the key target segments of the IBS patient population across the seven major markets
Quantify your press releases first, please.